Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and ...

Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against ...

"ESMO 2025: MSD’s ADC leapfrogs to Phase III in colorectal cancer " was originally created and published by Clinical Trials ...

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

In this episode, Ollie challenges himself with complex Korean verb forms and learns how to express seeing an imaginary dog ...

As of 2023, the ABC data indicated that in older adults (=65 years), the prevalence of invasive PD attributed to Capvaxive-unique serotypes was more than triple (34.8%) that of PCV20-unique serotypes ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...

VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel ...

OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug ...